Oct 22, 2025 9:15 am EDT OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Oct 17, 2025 9:15 am EDT OS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Oct 10, 2025 6:00 am EDT OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma
Oct 09, 2025 7:40 am EDT OS Therapies Provides Positive EMA Regulatory Update Following Positive Rapporteur Meeting
Sep 30, 2025 7:40 am EDT OS Therapies Provides OST-HER2 UK MHRA and US FDA Osteosarcoma Regulatory Update
Sep 19, 2025 7:40 am EDT OS Therapies to Participate in Spotlight Panel at BioFuture 2025 October 13 11:00am EDT
Sep 12, 2025 7:40 am EDT OS Therapies Announces Last Patient Enrolled in OST-504 (previously ADXS-504) Phase 1b Prostate Cancer Clinical Trial Completes Last Visit
Sep 03, 2025 7:40 am EDT OS Therapies to Participate in Upcoming Investor Conferences in September 2025
Sep 02, 2025 7:40 am EDT OS Therapies Provides OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Program Update Following FDA End of Phase 2 Meeting